

Is Dymista still hard to find in 2026? Get the latest on availability, pricing, and what you can do if your pharmacy is out of stock.
If you take Dymista for seasonal allergies, here's what you need to know about availability in 2026.
While Dymista hasn't faced a formal FDA-reported drug shortage like some medications, many patients continue to experience difficulty finding it at their local pharmacies — particularly during spring and fall allergy seasons. This guide covers the current state of Dymista availability, pricing, and practical steps you can take to get your prescription filled.
As of early 2026, Dymista is not listed on the FDA's official drug shortage database. This means there isn't a nationwide manufacturing or supply disruption for the medication.
However, that doesn't mean it's easy to find. Many patients report localized availability problems — meaning their specific pharmacy or area doesn't have Dymista in stock, even though the drug is technically being produced and distributed nationally. This distinction is important: just because the FDA doesn't list a shortage doesn't mean you won't have trouble finding it at your pharmacy.
Several factors contribute to the localized availability issues patients are experiencing:
Pharmacies order medications through wholesale distributors. These distributors use allocation systems that cap how much of a given drug a pharmacy can purchase in a given period. If your pharmacy has hit its allocation limit for Dymista or its generic equivalent, they can't order more until the next cycle — regardless of patient demand.
Dymista is primarily used for seasonal allergies, which means demand is highly cyclical. During peak allergy months (March through May and September through November), prescriptions for Dymista surge. Pharmacies that kept low inventory during off-season months may not have enough stock to meet the sudden increase in demand.
With the introduction of generic azelastine/fluticasone nasal spray, pharmacies now face a choice: stock the brand-name Dymista, one or more generic versions, or both. Many pharmacies opt to carry only the generic to save on inventory costs, which means patients with a brand-specific prescription may find their pharmacy doesn't carry it.
Brand-name Dymista typically costs between $200 and $300 for a single 23g bottle (approximately a 30-day supply). The generic version (azelastine/fluticasone nasal spray) has a retail price ranging from $150 to $250, but can be found for as low as $54 with a GoodRx coupon.
Insurance coverage for Dymista varies widely. Many commercial plans place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), resulting in copays of $40 to $75. The generic version may be covered at a lower tier. Be aware that many insurers require prior authorization and may enforce step therapy — meaning you'll need to try cheaper alternatives like over-the-counter Flonase or Astepro first.
The Dymista Copay Relief Card lets eligible commercially insured patients pay as little as $29 per prescription (maximum benefit of $150 per 30-day fill). This card is not available to patients on Medicare, Medicaid, or other government insurance programs.
For uninsured or underinsured patients, the Viatris Patient Assistance Program may provide Dymista at no cost to those who qualify based on income.
For more detailed savings strategies, see our complete guide: How to Save Money on Dymista in 2026.
A few developments have improved the Dymista landscape for patients:
If your pharmacy doesn't have Dymista, here are four steps that work:
Here's what to remember about Dymista in 2026:
More resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.